|
| Baseline | 4 weeks | 8 weeks |
Number of redness Lv. 1 | Placebo | 337.6 ± 448.8 | 391.4 ± 401.6 (53.8 ± 240.8) | 445.3 ± 390.9 (107.6 ± 332.7) |
Delphinol® | 596.9 ± 609.3 | 480.9 ± 623.0 (−116.0 ± 413.8) | 548.8 ± 690.5 (−48.1 ± 441.2) | |
Area of redness Lv. 1 | Placebo | 223.5 ± 424.5 | 315.4 ± 513.8 (91.9 ± 177.2) | 277.6 ± 363.2 (54.1 ± 192.3) |
Delphinol® | 393.5 ± 393.6 | 289.9 ± 274.6 (−103.6 ± 274.9) | 336.6 ± 346.8 (−59.9 ± 315.9) | |
Number of redness Lv. 2 | Placebo | 36.5 ± 84.4 | 65.4 ± 115.4 (28.9 ± 46.5) | 52.4 ± 73.1 (15.9 ± 51.8) |
Delphinol® | 64.1 ± 58.9 | 35.8 ± 30.0 (−28.4 ± 34.9)* | 53.9 ± 70.1 (−10.3 ± 43.6) | |
Area of redness Lv.2 | Placebo | 11.1 ± 23.6 | 21.0 ± 39.5 (9.9 ± 17.4) | 20.0 ± 36.1 (8.9 ± 16.4) |
Delphinol® | 20.6 ± 22.2 | 11.4 ± 11.7 (−9.3 ± 13.3)* | 21.4 ± 23.8 (0.8 ± 16.5) | |
Number of redness Lv. 3 | Placebo | 0.9 ± 2.1 | 2.0 ± 3.4 (1.1 ± 1.7) | 4.1 ± 7.1 (3.3 ± 5.4) |
Delphinol® | 2.4 ± 4.2 | 1.6 ± 2.6 (−0.8 ± 1.8) | 4.5 ± 7.3 (2.1 ± 3.8) | |
Area of redness Lv. 3 | Placebo | 0.1 ± 0.4 | 0.4 ± 1.1 (0.3 ± 1.2) | 0.6 ± 1.1 (0.5 ± 1.2) |
Delphinol® | 1.6 ± 3.1 | 0.9 ± 2.1 (−0.8 ± 1.5) | 1.8 ± 3.8 (0.1 ± 1.6) |